States Subpoena Schering-Plough For Vytorin Documents
This article was originally published in The Pink Sheet Daily
Executive Summary
Several states are seeking information relating to the ENHANCE trial, Vytorin promotion and stock sales by company executives.
You may also be interested in...
New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.
New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.
Cancer Signal Triggers Vytorin Study Review
Panel finds “no credible evidence” of increased cancer risk; SEAS trial misses its primary endpoint.